This study seeks to develop and test a novel digital pill system (DPS) that measures real-time medication ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention to provide personalized, data-driven adherence support, with the long-term goal of providing new and improved personalized support and increase medication adherence for people with AUD and ALD.
Being treated for AUD
Diagnosed with DSM-5 moderate to severe AUD
Screens positive ALD utilizing non-invasive blood tests
Planned initiation of acamprosate
History of hypersensitivity to acamprosate
Allergy to magnesium or silver
Severe renal impairment (creatinine clearance of 30mL/min or less)
Yale University
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator